Company Overview

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and cardiopulmonary diseases, with an emphasis on acute conditions with high unmet medical need. The company operates within the biotechnology and pharmaceutical development industry, primarily advancing proprietary drug candidates through clinical development rather than commercial sales. Windtree does not currently generate material product revenue and relies on equity financing, licensing arrangements, and collaborations to fund operations.

Windtree’s core strategic focus is on istaroxime, a novel investigational therapy being developed for cardiogenic shock and acute heart failure, conditions associated with high mortality and limited treatment options. The company evolved from its earlier identity as Discovery Laboratories, which historically focused on respiratory therapies, including synthetic surfactant technology. Over time, Windtree transitioned its strategy toward cardiovascular drug development, rebranding as Windtree Therapeutics to reflect this shift.

Business Operations

Windtree’s operations are centered on the research and clinical development of its lead cardiovascular drug candidates, with activities primarily consisting of clinical trial management, regulatory engagement, intellectual property management, and corporate administration. The company’s principal business segment is its cardiovascular therapeutic development program, anchored by istaroxime, which is designed to improve both cardiac contractility and relaxation through a differentiated mechanism of action.

The company operates predominantly in the United States, with international exposure through licensing and development agreements. Windtree does not maintain manufacturing facilities and instead relies on third-party contract research organizations and manufacturers. A key partnership includes a regional licensing arrangement with Lee’s Pharmaceutical Holdings Limited for the development and commercialization of istaroxime in Greater China, providing Windtree with milestone and royalty opportunities while limiting direct operational burden.

Strategic Position & Investments

Windtree’s strategic direction is focused on advancing istaroxime through later-stage clinical development and positioning the asset for potential partnering, licensing, or acquisition opportunities. The company prioritizes indications such as cardiogenic shock, where there are no FDA-approved therapies and where clinical differentiation could support regulatory and commercial value. Growth initiatives are largely clinical and regulatory in nature rather than expansion of commercial infrastructure.

The company’s investment activity is concentrated on internal research and development rather than acquisitions. Windtree has no significant portfolio of operating subsidiaries and does not function as a holding company. Emerging areas of focus include refining the clinical profile of istaroxime and exploring additional cardiovascular indications where its dual mechanism may offer advantages over existing therapies. Data on additional late-stage assets beyond istaroxime is limited, and public disclosures indicate a narrow but targeted development pipeline.

Geographic Footprint

Windtree Therapeutics is headquartered in the United States, with corporate and executive operations based domestically. Its clinical development activities are primarily conducted in North America, supported by global clinical research organizations as needed. The company does not report significant physical infrastructure or employee bases outside the U.S.

Internationally, Windtree’s presence is largely strategic rather than operational. Through its licensing agreement with Greater China, the company maintains indirect exposure to Asia-Pacific markets, particularly China, without direct commercialization responsibilities. Outside of this region, Windtree’s influence remains limited, and there is no verified evidence of substantial operations in Europe, Latin America, or Africa beyond potential clinical trial sites.

Leadership & Governance

Windtree is led by an executive team with experience in biotechnology development, capital markets, and clinical research. Leadership emphasizes disciplined capital allocation, partnering strategies, and advancing high-impact therapies for acute cardiovascular conditions. The company is governed by a board of directors that provides oversight typical of U.S.-listed clinical-stage biotechnology firms.

Key executives include:

• Jed Latkin – President and Chief Executive Officer
• David McDunn – Chief Financial Officer
• Steven R. Simonson, M.D. – Chief Medical Officer

Public disclosures consistently identify Jed Latkin as the company’s strategic leader, with a stated focus on maximizing the value of Windtree’s cardiovascular assets through clinical execution and external partnerships. Information regarding additional executive officers or recent leadership changes beyond these roles is data inconclusive based on available public sources.